Bob Nelsen woos John Maraganore to his first VC post after retiring from Alnylam
After almost two decades of primarily being known as Alnylam’s CEO, John Maraganore is getting a new, prominent title.
Maraganore is among a slate of new venture partners at ARCH Venture, joining alongside ex-FDA official Luciana Borio, Jake Bauer (previously at MyoKardia), Axel Bouchon (former head of Leaps by Bayer) and Sabah Oney (of Alector fame).
The move was hardly surprising. Maraganore has made it clear that his retirement, which is scheduled for the end of the year, signaled a shift into a new phase of his career where, instead of hands-on parenting, he wanted to be like a “grandfather” to the next generation of biotech startups, imparting hard-earned wisdom about the treacherous journey from the lab to market — one he personally shepherded Alnylam and its RNAi science through.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.